patent.fyi
Applications  /  US 2026/0355147
United States Patent Application Publication

US 2026/0355147 A1

Published
Nov 12, 2026
Filed
May 28, 2024
Earliest date on the face
May 26, 2023
Classification
A61K 31/37
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Ubiquinone supports electron transfer

What ifWhat if the composition contained ubiquinone and trigonelline and was free of urolithins and their salts?
Claim language“a urolithin or a pharmaceutically acceptable salt thereof”

A lipid phase carries ubiquinone, and an aqueous phase carries trigonelline. In the inner mitochondrial membrane, ubiquinone accepts electrons from complexes I and II and transfers them to complex III.

1.1Riboflavin supplies respiratory cofactors

What ifWhat if the composition contained riboflavin and trigonelline and was free of urolithins and their salts?
Claim language“a urolithin or a pharmaceutically acceptable salt thereof”

The formulation combines riboflavin and trigonelline in a dry powder. Cells convert riboflavin to flavin mononucleotide and flavin adenine dinucleotide, which serve as redox cofactors in respiratory complexes I and II, respectively.

1.1Carnitine supports fatty acid transport

What ifWhat if the composition contained L-carnitine and trigonelline and was free of urolithins and their salts?
Claim language“a urolithin or a pharmaceutically acceptable salt thereof”

L-carnitine and trigonelline dissolve in water to form an oral solution. The mitochondrial carnitine shuttle transfers long-chain fatty acyl groups into the matrix as acylcarnitines and regenerates fatty acyl-CoA for beta oxidation.

1.2Nicotinamide feeds NAD salvage

What ifWhat if the composition contained a urolithin and nicotinamide and was free of trigonelline and its salts?
Claim language“trigonelline or a pharmaceutically acceptable salt thereof”

A dry capsule combines nicotinamide with micronized urolithin powder. The NAD salvage pathway converts nicotinamide to nicotinamide mononucleotide and then to NAD+, a cofactor for mitochondrial fuel oxidation.

1.2Nicotinic acid supplies NAD precursor

What ifWhat if the composition contained a urolithin and nicotinic acid and was free of trigonelline and its salts?
Claim language“trigonelline or a pharmaceutically acceptable salt thereof”

A tablet combines nicotinic acid and urolithin with microcrystalline cellulose. Cells convert nicotinic acid to nicotinic acid mononucleotide, then to nicotinic acid adenine dinucleotide, and finally to NAD+.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Paired analytes for laboratory training

A laboratory training kit contains a dry mixture of urolithin A and trigonelline with an assigned mass for each analyte. The operator extracts a weighed portion with aqueous methanol and divides the filtered extract between reversed-phase and hydrophilic interaction liquid chromatography methods. The operator calculates the recovery of each analyte from its assigned mass and measured concentration.

Component substitution

Urolithin B replaces urolithin A

A two-component test blend uses urolithin B in place of urolithin A and retains trigonelline. The operator weighs both powders on a dry-mass basis and mixes them by tumbling in a sealed vessel. Separate chromatographic assays measure the content of each component in samples drawn from several locations in the blend.

Parameter or scale variation

Five ratios at fixed total mass

Five bench batches each contain 10 grams of combined urolithin A and trigonelline on a dry-mass basis. The urolithin A to trigonelline mass ratios are 1:9, 1:3, 1:1, 3:1, and 9:1. The operator tumble-mixes each batch for 15 minutes at 30 revolutions per minute and assays three subsamples from each batch.

Combination with existing systems

Twin feeders supply a continuous blender

Separate loss-in-weight screw feeders meter urolithin A and trigonelline into a continuous paddle blender. The feeder setpoints establish the mass ratio, and the sum of the feed rates establishes the blend throughput. A timed sampler collects portions from the discharge stream for separate assays of both components.

Separate granules share a capsule

A roller compactor processes urolithin A and trigonelline in separate runs, and a mill breaks each compacted ribbon into granules. Two dosing stations on a capsule filler deposit measured quantities of the respective granules into the same capsule body before the closing station seats the cap. Assays on individual capsules measure the fill content of each component.

Automated or data-driven variant

Software checks powder dosing ratios

A controller reads a balance under a receiving vessel and records the mass added by the urolithin A feeder and the trigonelline feeder in sequence. After each addition, the controller waits for a stable reading and calculates the delivered mass from the change in vessel weight. The controller starts the mixer when both delivered masses are within 2 percent of their respective setpoints and flags the vessel for rework otherwise.

Specific version of a part

Micronized urolithin A suspension

Micronized urolithin A forms the solid phase of an aqueous suspension. Polysorbate 80 wets the particles, and xanthan gum increases the viscosity of the liquid to slow settling.

Urolithin B dry capsule

Milled crystalline urolithin B is blended with microcrystalline cellulose. The dry blend fills a two-piece hydroxypropyl methylcellulose capsule.

Dissolved trigonelline in buffered water

Trigonelline in its zwitterionic form dissolves in purified water. A citrate buffer sets the pH of the aqueous formulation to 5.5.

Trigonelline hydrochloride compressed tablet

Crystalline trigonelline hydrochloride is blended with mannitol and crospovidone before compression. Crospovidone promotes tablet breakup on contact with water, exposing the salt for dissolution.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2016/0279097 A1
Published
Sep 29, 2016
Filed
Oct 15, 2014
Class
A61K 31/37
Document BUS 2022/0249453 A1
Published
Aug 11, 2022
Filed
Jul 3, 2020
Class
A61K 31/4425
Claim 1
Document A
Document B
1.1a urolithin or a pharmaceutically acceptable salt thereof
Pharmaceutical composition comprising an effective amount of at least one urolithin chosen in the group consisting of: urolithin A, urolithin B, urolithin C, urolithin D and a combination thereof, and a pharmaceutically acceptable vehicle.
A · US 2016/0279097 A1 · claim 29
1.2trigonelline or a pharmaceutically acceptable salt thereof.
As used herein, “trigonelline” is any compound comprising 1-methylpyridin-1-ium-3-carboxylate including, for example, any salt thereof (e.g., Chloride or Iodide salt) and/or a form in which the ring therein may be reduced.
B · US 2022/0249453 A1 · ¶ 71

An empty cell means only that no passage was reproduced there.

Statements in these documents
Although some positive results were obtained, a compound both efficient and devoid of long term side-effects is still required.
A · US 2016/0279097 A1 · ¶ 5
The present invention first relates to a composition comprising urolithin A, urolithin B, urolithin C, urolithin D or a combination thereof intended for its use for the stimulation of insulin secretion, and to a composition comprising urolithin B, urolithin C, urolithin D or a combination thereof intended for its use for the treatment or the prevention of diabetes mellitus.
A · US 2016/0279097 A1 · ¶ 1
Intracellular levels of NAD+ can be increased in cells and tissues to improve cell and tissue survival and/or or overall cell and tissue health.
B · US 2022/0249453 A1 · ¶ 1
In an embodiment, the composition is selected from the group consisting of a food product, a food supplement, an oral nutritional supplement (ONS), a medical food, and combinations thereof.
B · US 2022/0249453 A1 · ¶ 7
Cite aspatent.fyi, US 2026/0355147 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355147/, SHA-256 e409ceb25545a86709e7d02d46194c247756d9d2b447a59c9d7ecf6a7a117368
First published
Permanent addresshttps://patent.fyi/US20260355147/
Content fingerprint (SHA-256)e409ceb25545a86709e7d02d46194c247756d9d2b447a59c9d7ecf6a7a117368
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi